Eikon Therapeutics Updates Corporate Presentation (Reg FD Disclosure)

What Happened Eikon Therapeutics, Inc. announced an updated corporate presentation on August 13, 2026 and furnished that presentation on a Form 8-K filed with the SEC (filed August 14, 2026). The updated presentation is provided as Exhibit 99.1 to the 8-K. The report was signed by Alfred Bowie, Ph.D., Chief Financial Officer, on August 13, 2026.

Key Details

• The company updated its corporate presentation on August 13, 2026 and furnished it to the SEC as Exhibit 99.1.
• The Form 8-K reporting the update was filed with the SEC on August 14, 2026.
• The disclosure was made under Regulation FD (Reg FD), indicating public distribution of the presentation.
• The filing was signed by CFO Alfred Bowie, Ph.D.

Why It Matters Furnishing an updated corporate presentation under Reg FD means Eikon is publicly distributing its investor presentation so all investors have access to the same information. The 8-K itself simply furnishes the presentation; investors should review Exhibit 99.1 (and the company’s investor relations materials) for any specifics on strategy, pipeline, or financial guidance that could affect investment decisions.